Israel: $35 million acquisition probably off the table due to disagreements

Back in February, InterCure announced that it had signed a definitive agreement with Better. Under the terms of the agreement, InterCure would acquire 100% of Better’s shares, which includes “Better’s” unique strains, cultivation site, intellectual property, and commercial operations in Israel as well its international activities. 

Now, InterCure provided an update that there are some fundamental disagreements between the parties (including open matters which were not concluded at the time of the signing of the agreement), in addition to a disconnect between the parties, which poses doubts as to whether the $35 million acquisition will in fact be completed.   

For more information:
InterCure
intercure.co